Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Gross Margin (2022 - 2025)

Historic Gross Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 34.84%.

  • bioAffinity Technologies' Gross Margin fell 38800.0% to 34.84% in Q3 2025 from the same period last year, while for Sep 2025 it was 27.86%, marking a year-over-year decrease of 71700.0%. This contributed to the annual value of 36.09% for FY2024, which is 48300.0% up from last year.
  • bioAffinity Technologies' Gross Margin amounted to 34.84% in Q3 2025, which was down 38800.0% from 19.92% recorded in Q2 2025.
  • bioAffinity Technologies' Gross Margin's 5-year high stood at 93.75% during Q2 2023, with a 5-year trough of 19.92% in Q2 2025.
  • Over the past 4 years, bioAffinity Technologies' median Gross Margin value was 40.01% (recorded in 2024), while the average stood at 55.54%.
  • Over the last 5 years, bioAffinity Technologies' Gross Margin had its largest YoY gain of 49300bps in 2023, and its largest YoY loss of -677600bps in 2023.
  • bioAffinity Technologies' Gross Margin (Quarter) stood at 92.54% in 2022, then tumbled by -73bps to 24.78% in 2023, then increased by 18bps to 29.24% in 2024, then increased by 19bps to 34.84% in 2025.
  • Its Gross Margin was 34.84% in Q3 2025, compared to 19.92% in Q2 2025 and 26.21% in Q1 2025.